NVO
Novo Nordisk A/S
NVO has a slight edge over QTRX overall, supported by lower modeled downside and stronger fundamentals.
QTRX
Quanterix Corporation
QTRX offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
QTRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Unavailable |
QTRX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
QTRX PE Valuation
QTRX has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
QTRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect QTRX's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over QTRX on earnings quality, reporting a profit while its opponent remains loss making.
QTRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.35 | -$0.02 |
| Q2 2026 | -$2.62 | -$0.80 |
| Q1 2026 | -$2.35 | -$1.11 |
| Q4 2025 | -$2.51 | -$1.51 |
| Q3 2025 | -$2.33 | -$1.40 |
| Q2 2025 | -$1.82 | -$0.90 |
| Q1 2025 | -$1.24 | -$0.35 |
| Q4 2024 | -$1.00 | -$0.24 |
QTRX lost $2.35 per share over the past year, about the same as its loss the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over QTRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over QTRX on profitability, with a higher operating margin.
QTRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35M | -13% |
| Q2 2026 | $32.9M | +34% |
| Q1 2026 | $36.4M | +20% |
| Q4 2025 | $43.9M | +25% |
| Q3 2025 | $40.2M | +12% |
| Q2 2025 | $24.5M | -29% |
| Q1 2025 | $30.3M | -5.4% |
| Q4 2024 | $35.2M | +11% |
QTRX's revenue is growing: $35M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -64% | +29 points |
| Q2 2026 | -150% | +1.4 points |
| Q1 2026 | -114% | -27 points |
| Q4 2025 | -56% | -14 points |
| Q3 2025 | -93% | -60 points |
| Q2 2025 | -152% | -120 points |
| Q1 2025 | -87% | -40 points |
| Q4 2024 | -42% | +1.2 points |
QTRX's operating margin was −64% last quarter, up 28 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over QTRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
QTRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.3M | +$25.6M |
| Q2 2026 | -$5.2M | +$1.2M |
| Q1 2026 | -$18.2M | -$3.1M |
| Q4 2025 | -$16.3M | -$11.6M |
| Q3 2025 | -$41.9M | -$35.3M |
| Q2 2025 | -$6.4M | +$118K |
| Q1 2025 | -$15.1M | +$5.5M |
| Q4 2024 | -$4.7M | +$3.4M |
QTRX has burned cash in almost every quarter: −$56M over the past year, against −$68M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over QTRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
QTRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +221K shares |
| 1 year | +2.9% | +1.3M shares |
| 3 years | +26% | +9.7M shares |
| 5 years | +30% | +10.9M shares |
| Available history | +69% | +19.4M shares |
QTRX has 47M diluted shares, up 2.9% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
QTRX Net Leverage
QTRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
QTRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 39.4 | Neutral |
QTRX's weekly RSI is 43 (neutral) and its Stochastic is 39 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
QTRX PE vs Healthcare Sector
QTRX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over QTRX on trend strength, trading above more of its moving averages.
QTRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.07 | 6.8% below |
| 20 week MA | $3.22 | 11% below |
| 50 week MA | $4.24 | 33% below |
| 100 week MA | $5.37 | 47% below |
| 200 week MA | $11.9 | 76% below |
QTRX is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over QTRX on returns for 2026, with the stronger performance.
QTRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.5 | $45.9 | +95% |
| 2021 | $45.9 | $43.9 | -4.5% |
| 2022 | $43.9 | $12.9 | -71% |
| 2023 | $12.9 | $27.3 | +112% |
| 2024 | $27.3 | $11.1 | -60% |
| 2025 | $11.1 | $6.46 | -42% |
| 2026 YTD | $6.46 | $2.86 | -56% |
QTRX's yearly returns have swung widely, from +112% in 2023 to −71% in 2022. It's down 56% so far in 2026.